

CERTIFICATE OF MAILING

that this paper or fee is being deposited with the United States Postal Service with sufficient postage as unsubstance for Patents, Washington, D.C. 2020 on this date listed below.

Mary & Zimmerman

FEB 2 1 2003

IN THE UNITED STATES PATENT AND TRADEMARK OF MCE CENTER 1600/2900 I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C.

In re Application for:

Charles A. NICOLETTE

Serial No.: 09/931,969

Filing Date: August 17, 2001

For: THERAPEUTIC COMPOUNDS FOR

OVARIAN CANCER

Examiner: Not Yet Assigned

Group Art Unit: 1614

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached forms PTO-1449a and PTO-1449b are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as se
forth in 37 C.F.R. § 1.491.

	Before the mailing date of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-2518 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
This Informa	tion Disclosure Statement is filed:
	After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to charge Deposit Account No.[] for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.
This Informa	ation Disclosure Statement is filed:
	After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.
The undersig	ened certifies that:
	Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
	No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
II. Copies o	of the Cited Items:
\boxtimes	Copies of all of the items listed on the attached Form PTO-1449 are enclosed.

Serial No. 09/931,969 Docket No. GZ 2104.00

	Copies of only the following items listed on the attached Form PTO-1449 are enclosed:
	Copies of the items listed in the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. [] filed [] and relied upon in this application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).
	Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.
III. Concise	Explanation of Relevance:
\boxtimes	A concise explanation of relevance of the items listed on Form PTO-1449 is not given.
	A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).
IV. Related	Applications:
	Applicants bring to the Office's attention the following related, co-pending application(s):
V. Conclus	sion:
Citation of the	e above documents shall not be construed as:
1.	an admission that the documents are necessarily prior art with respect to the instant invention;
2.	a representation that a search has been made, other than as described above; or
3.	an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks. The Commissioner is hereby authorized to charge Deposit Account No. 50-2518, billing reference number: 19442-7235 for any additional fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,

Dated: Leb. 12, 2003

Antoinette F. Konski Registration No. 34,202

Bingham McCutchen LLP (formerly McCutchen Doyle Brown & Enersen LLP)

Three Embarcadero Center, Suite 1800 San Francisco, California 94111-4067

Telephone: (650) 849-4850 Facsimile: (650) 849-4800

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Papagorian Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

form1449A-PTO

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1


Complete if Known				
Application Number	09/931,969			
Filing Date	August 17, 2001			
First Named Inventor	Charles A. NICOLETTE			
Art Unit	1614			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	GZ 2104.00			

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No. ¹	Number – Kind Code ² (if known)	MM-DD-YY	Application of Cited Document	Where Relevent Passages or Relevant Jim ex Aprear
					70517
					FEB 2 1 200
					TECH CENTER
				- 4.007	1000/

· · · · · · · · · · · · · · · · · · ·		FOREIGN PAT	ENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	 T ⁴
	_ 1	WO 00/43511	07-27-00	Smithkline Beecham Biologicals S.A.		
		·				
,						

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered



¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

nder the Paperwork	duction Act of 1995,	no persons a	re required to respo	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number.				
FEB 1 9 2003 E	3			Complete if Known				
ostitute for form 144	7 РТО			Applicati n Numb r	09/931,969			
STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	August 17, 2001			
				First Named Inventor	Charles A. NICOLETTE			
				Art Unit	1614			
				Examiner Name	Not Yet Assigned			
Sheet	1	of	1	Attorney Docket Number	GZ 2104.00			

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
/	/ 1	Hsu, C.T. et al. (July 2000) "Vaccination Against Gonadotropin-Releasing Hormone (GnRH) Using Toxin Receptor- Binding Domain-Conjugated GnRH Repeats" Cancer Res. 60:3701-3505	
/	2	Joberty, G. et al. (Aug. 2000) "The Cell-Polarity Protein Par6 Links Par3 and atypical protein kinase C to Cdc42" Nature Cell Biol. 2(8):531-539	
			ļ .
Examiner's Signature		Date Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.